Total Payments
$226.64
2023 Payments
$12.89
Companies
5
Transactions
20
Medicare Patients
4,964
Medicare Billing
$293,718
Payment Breakdown by Category
Food & Beverage$147.14 (64.9%)
Education$79.50 (35.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $147.14 | 18 | 64.9% |
| Education | $79.50 | 2 | 35.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $150.10 | 14 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $38.91 | 3 | $0 (2022) |
| Dermavant Sciences, Inc. | $12.89 | 1 | $0 (2023) |
| Incyte Corporation | $12.51 | 1 | $0 (2022) |
| VYNE Pharmaceuticals Inc. | $12.23 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $12.89 | 1 | Dermavant Sciences, Inc. ($12.89) |
| 2022 | $163.42 | 16 | Janssen Biotech, Inc. ($124.46) |
| 2021 | $38.10 | 2 | Janssen Biotech, Inc. ($25.64) |
| 2020 | $12.23 | 1 | VYNE Pharmaceuticals Inc. ($12.23) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/15/2023 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2022 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $5.46 | General |
| Category: Immunology | ||||||
| 09/14/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $66.99 | General |
| Category: Immunology | ||||||
| 08/31/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $3.98 | General |
| Category: Immunology | ||||||
| 08/26/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $4.72 | General |
| Category: Immunology | ||||||
| 08/10/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: Immunology | ||||||
| 08/01/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $3.15 | General |
| Category: Immunology | ||||||
| 08/01/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $1.35 | General |
| Category: Immunology | ||||||
| 07/25/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $2.32 | General |
| Category: Immunology | ||||||
| 07/18/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $2.56 | General |
| Category: Immunology | ||||||
| 07/11/2022 | Incyte Corporation | OPZELURA (Drug) | Education | Cash or cash equivalent | $12.51 | General |
| Category: Dermatology | ||||||
| 07/07/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $0.94 | General |
| Category: Immunology | ||||||
| 06/15/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $3.35 | General |
| Category: Immunology | ||||||
| 04/28/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: Immunology | ||||||
| 03/16/2022 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: IMMUNOLOGY | ||||||
| 01/05/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: Immunology | ||||||
| 10/20/2021 | Janssen Biotech, Inc. | REMICADE (Biological), STELARA, SIMPONI ARIA | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: Immunology | ||||||
| 08/26/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: IMMUNOLOGY | ||||||
| 06/17/2020 | VYNE Pharmaceuticals Inc. | AMZEEQ (Drug) | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: Treatment of ACNE Vulgaris | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 715 | 901 | $80,960 | $36,369 |
| 2022 | 15 | 1,340 | 1,824 | $157,980 | $80,887 |
| 2021 | 14 | 1,475 | 2,072 | $179,325 | $98,826 |
| 2020 | 14 | 1,434 | 1,986 | $156,215 | $77,636 |
Total Patients
4,964
Total Services
6,783
Medicare Billing
$293,718
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 195 | 231 | $23,100 | $11,894 | 51.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 167 | 186 | $13,950 | $5,927 | 42.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 67 | 71 | $10,295 | $4,240 | 41.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 80 | 90 | $9,900 | $4,235 | 42.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 61 | 70 | $5,600 | $2,492 | 44.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 26 | $3,640 | $2,026 | 55.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $3,720 | $1,576 | 42.4% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 13 | $3,250 | $1,315 | 40.5% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 11 | $1,375 | $1,016 | 73.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 38 | 140 | $3,500 | $618.12 | 17.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 14 | 14 | $1,190 | $576.20 | 48.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 17 | 18 | $1,440 | $452.96 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 276 | 359 | $35,900 | $21,341 | 59.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 363 | 460 | $34,500 | $16,323 | 47.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 156 | 184 | $20,240 | $11,631 | 57.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 125 | 152 | $12,160 | $6,003 | 49.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 81 | 89 | $12,905 | $5,823 | 45.1% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 71 | 71 | $6,035 | $3,371 | 55.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 51 | 51 | $6,120 | $3,290 | 53.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 31 | 34 | $4,250 | $2,972 | 69.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 48 | 79 | $6,320 | $2,788 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 18 | $2,520 | $1,651 | 65.5% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 11 | 12 | $3,000 | $1,514 | 50.5% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2022 | 13 | 13 | $3,900 | $1,504 | 38.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 72 | 274 | $6,850 | $1,301 | 19.0% |
About Dr. Kenneth Mink, MD
Dr. Kenneth Mink, MD is a Procedural Dermatology healthcare provider based in Erie, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1932102829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Mink, MD has received a total of $226.64 in payments from pharmaceutical and medical device companies, with $12.89 received in 2023. These payments were reported across 20 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($147.14).
As a Medicare-enrolled provider, Mink has provided services to 4,964 Medicare beneficiaries, totaling 6,783 services with total Medicare billing of $293,718. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Procedural Dermatology
- Location Erie, PA
- Active Since 05/24/2005
- Last Updated 11/28/2007
- Taxonomy Code 207NS0135X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1932102829
Products in Payments
- TREMFYA (Drug) $84.14
- REMICADE (Biological) $65.96
- COSENTYX (Biological) $38.91
- VTAMA (Drug) $12.89
- OPZELURA (Drug) $12.51
- AMZEEQ (Drug) $12.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.